Recent Updates
Recently added Catalysts

Tiotropium

Phase 1

Healthy | Small molecule | Other |3M Company|Last Updated: Dec 4, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedACTIVE_CONTROLLEDBiomarker
Total Trials1
Total Enrollment40
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT03246581Two-period 21 Day Cross-over Study to Compare the Pharmacokinetics of Tiotropium From Two InhalersPHASE1 COMPLETED 40Jul 13, 2017May 3, 2018Dec 4, 20251 United Kingdom
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Peak Plasma Concentration (Cmax)
24 hours

noncompartmental analysis

Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeBASIC_SCIENCE
Treatment Arms
ArmTypeDescription
Test ProductEXPERIMENTALtiotropium pMDI 2 inhalations
Commercial ProductACTIVE_COMPARATORtiotropium pMDI 2 inhalations
Interventions
NameTypeDescription
TiotropiumDRUGinhalation
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 55 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Healthy Volunteer * Willing and able to give informed consent * Willing to withhold all alcoholic beverages for 48 hours and all xanthine- containing foods and beverages for 24 hours prior to reporting to clinic * Subjects must agree to use an adequate method of contraception ...

Countries:United Kingdom
Unlock Eligibility Criteria